Hydroxyethyl-Starch Solutions To Be Pulled From EU Market
Member States Can Temporarily Delay Suspension Citing Public Health Considerations
Executive Summary
Hydroxyethyl-starch solutions are being suspended from the EU following the failure of several safety measures that were introduced to prevent their use in certain high-risk patient groups.
You may also be interested in...
Rise in patient reporting boosts EU drug safety signals
The introduction of direct reporting of adverse drug reactions by patients in Europe appears to have had the desired effect: in 2013, the number of ADRs reported by patients within the European Economic Area rose by more than 50% as a result of greater public awareness of the importance of such reporting.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
OIG: FDA’s EUA Approach Allowed Bad Tests To Reach Market
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.